Alcon (ALC) Q2 2025 earnings summary

Executive summary

• Net sales increased 4% year-over-year to $2.6B in Q2 2025, driven by Vision Care and Consumables, while Implantables and Equipment sales declined due to soft market and competition.

• Completed or announced major acquisitions, including STAAR Surgical ($1.5B), Aurion Biotech ($522M), and Cylite Pty Ltd. ($72M), expanding presence in myopia, ICL, and surgical technology markets.

• Operating income declined 22% in Q2 due to product discontinuation charges and higher R&D, but rose 4% for the first half, aided by investment gains.

• IFRS diluted EPS for Q2 was $0.35, down 22% year-over-year, impacted by $44M in charges for discontinued Vision Care product; core diluted EPS was $0.76, up 1% year-over-year.

• Launched new products including Unity VCS, PanOptix Pro, and Tryptyr, reinforcing leadership in eye care.

Significant events and developments

• Announced and/or completed $1.5B acquisition of STAAR Surgical, expanding into the ICL market, with expected EPS accretion in year two post-close.

• Acquired LumiThera and its Valeda Light Delivery System, the first FDA-authorized device for early/intermediate dry AMD, with peak recurring revenue potential of $100M-$150M by 2030.

• Acquired majority interest in Aurion Biotech ($522M) and full ownership of Cylite Pty Ltd. ($72M), expanding Vision Care and Surgical portfolios.

• Launched Unity VCS and PanOptix Pro, and received FDA approval for Tryptyr, a first-in-class dry eye prescription drop.

• Impairment charges of $43M recognized in Vision Care due to product discontinuation.

Segment performance

• Q2 2025 sales: Surgical $1.5B (up 2%), Vision Care $1.1B (up 6%); Consumables up 6%, Implantables down 2%.

• Vision Care growth driven by 9% increase in Contact Lenses and improved margins; ocular health up 2%, with some pressure from China divestment.

• Segment contribution in Surgical fell 6% due to higher costs and R&D; Vision Care contribution up 16%.

• 1H 2025 sales split: Vision Care $2.2B (45%), Surgical $2.8B (55%).

• Equipment sales slightly down; international markets drove growth in Consumables and Contact Lenses.